These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 14165678)

  • 21. [On the coagulation factors from V through XIII].
    Yoshida K; Tagawa N
    Nihon Rinsho; 1973 Apr; 31(4):755-64. PubMed ID: 4580392
    [No Abstract]   [Full Text] [Related]  

  • 22. Two-stage procedure for the quantitative determination of autoprothrombin 3 concentration and some applications.
    Reno RS; Seegers WH
    Thromb Diath Haemorrh; 1967 Aug; 18(1-2):198-210. PubMed ID: 4169263
    [No Abstract]   [Full Text] [Related]  

  • 23. MODIFICATIONS OF THE COAGULATION MECHANISM DURING PREGNANCY.
    PHILLIPS LL
    Mod Trends Hum Reprod Physiol; 1963; 15():190-204. PubMed ID: 14115154
    [No Abstract]   [Full Text] [Related]  

  • 24. THE EFFECT OF LANTHANIDES AND ACTINIDES ON BLOOD COAGULATION. I. EVIDENCE FOR THE PROPERTIES OF A NEW SERUM THROMBOPLASTIC FACTOR.
    COLMAN R; ALEXANDER B
    J Clin Invest; 1964 Apr; 43(4):705-19. PubMed ID: 14153486
    [No Abstract]   [Full Text] [Related]  

  • 25. Inhibition of the activation of Hageman factor (factor XII) and of platelet aggregation by extracts of Brugia malayi microfilariae.
    Foster CB; Flanigan TP; Kazura JW; Dumenco LL; Ratnoff OD
    J Lab Clin Med; 1991 May; 117(5):344-52. PubMed ID: 1902251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blood coagulation. Role of Hageman protein (F-XII) and autoprothrombin II (F-IX?) in the activation of autoprothrombin 3 (F-X).
    Seegers WH; Grammens GL; McCoy LE
    Thromb Diath Haemorrh; 1970 Dec; 24(3):345-51. PubMed ID: 5533980
    [No Abstract]   [Full Text] [Related]  

  • 27. Rapid loss of factor XII and XI activity in ellagic acid-activated normal plasma: role of plasma inhibitors and implications for automated activated partial thromboplastin time recording.
    Joist JH; Cowan JF; Khan M
    J Lab Clin Med; 1977 Dec; 90(6):1054-65. PubMed ID: 303667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. THROMBOPLASTIN FORMATION.
    POOL JG
    Annu Rev Med; 1964; 15():215-32. PubMed ID: 14133846
    [No Abstract]   [Full Text] [Related]  

  • 29. COAGULATION FACTORS IN NORMAL AND HEMOPHILIAC-TYPE SWINE.
    CORNELL CN; MUHRER ME
    Am J Physiol; 1964 Apr; 206():926-8. PubMed ID: 14166196
    [No Abstract]   [Full Text] [Related]  

  • 30. Inhibition of the activation of Hageman factor (factor XII) by peripheral blood cells.
    Ratnoff OD; Emanuelson MM; Ziats NP
    J Clin Invest; 1987 Oct; 80(4):1180-9. PubMed ID: 3498741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Importance of factor-IX-dependent prothrombinase formation--the Josso pathway--in clotting plasma.
    Xi M; Béguin S; Hemker HC
    Haemostasis; 1989; 19(6):301-8. PubMed ID: 2620866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prothrombin utilization in congenital coagulation deficiency states.
    Owen CA; Thompson JH
    Thromb Diath Haemorrh; 1971 Jun; 25(2):297-311. PubMed ID: 5568049
    [No Abstract]   [Full Text] [Related]  

  • 33. Surgical care of patients with hereditary disorders of blood coagulation.
    Shulman NR
    Mod Treat; 1968 Jan; 5(1):61-83. PubMed ID: 4870180
    [No Abstract]   [Full Text] [Related]  

  • 34. [STUDIES ON FACTOR IX ACTIVITY. I. RELATION BETWEEN SERUM THROMBOPLASTIN GENERATION TEST AND WHOLE BLOOD CLOTTING TIME, WITH SPECIAL REFERENCE TO THE MODE OF ACTION OF FACTOR IX AND CONTACT FACTOR].
    MATSUOKA T
    Nihon Ketsueki Gakkai Zasshi; 1963 Apr; 26():231-43. PubMed ID: 14043489
    [No Abstract]   [Full Text] [Related]  

  • 35. Inhibition of ellagic acid-activated Hageman factor (factor XII) and Hageman factor fragments by popcorn inhibitor.
    Ratnoff OD; Moneme V
    Proc Soc Exp Biol Med; 1981 Feb; 166(2):297-9. PubMed ID: 7208489
    [No Abstract]   [Full Text] [Related]  

  • 36. [BLOOD CLOTTING FACTOR IN HEMOLYSATES].
    OGIWARA Y
    Nihon Ketsueki Gakkai Zasshi; 1963 Dec; 26():779-87. PubMed ID: 14154695
    [No Abstract]   [Full Text] [Related]  

  • 37. Inhibition of the activation of Hageman factor (factor XII) by soluble human placental collagens types III, IV, and V.
    Koenig JM; Chahine A; Ratnoff OD
    J Lab Clin Med; 1991 Jun; 117(6):523-7. PubMed ID: 1646270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. THE ACTIVATION OF FACTOR X BY EXTRACTS OF RABBIT BRAIN.
    NEMERSON Y; SPAET TH
    Blood; 1964 May; 23():657-68. PubMed ID: 14142504
    [No Abstract]   [Full Text] [Related]  

  • 39. Some effects of a microcrystalline collagen preparation on blood.
    Mason RG; Read MS
    Haemostasis; 1974; 3(1):31-45. PubMed ID: 4215704
    [No Abstract]   [Full Text] [Related]  

  • 40. The role of prekallikrein and high-molecular-weight kininogen in the contact activation of Hageman factor (factor XII) by sulfatides and other agents.
    España F; Ratnoff OD
    J Lab Clin Med; 1983 Oct; 102(4):487-99. PubMed ID: 6604770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.